Medical Microbiology and Immunology

, Volume 167, Issue 1, pp 1–9

A clinical trial with Alice/R-75 strain, live attenuated serum inhibitor-resistant intranasal bivalent influenza A/B vaccine

  • Mary J. Spencer
  • James D. Cherry
  • Keith R. Powell
  • Ciro V. Sumaya
Article

DOI: 10.1007/BF02123290

Cite this article as:
Spencer, M.J., Cherry, J.D., Powell, K.R. et al. Med Microbiol Immunol (1979) 167: 1. doi:10.1007/BF02123290

Abstract

A clinical trial was conducted with Alice/R-75 strain live attenuated intranasal influenza A/B vaccine. With double blind control 88 adult volunteers were administered 2 doses of Alice/R-75 vaccine, 93 volunteers received one dose of Alice/R-75 vaccine and one dose placebo solution and 94 subjects were administered 2 doses of placebo solution. Twenty-three other subjects received Alice strain monovalent influenza A vaccine. For comparison, data from 21 subjects who received monovalent intranasal R-75 strain influenza B in two doses is included. The vaccine was generally well tolerated. Four-fold serum hemagglutination-inhibiting (HAI) antibody titer rises to A/England/42/72 occurred in 39% of the monovalent Alice strain vaccinees; in contrast 18% of those given 2 doses of bivalent Alice/R-75 vaccine and 11% of those given 1 dose of bivalent vaccine had similar four-fold HAI antibody titer rises. HAI antibody titer rises to influenza B/Hong Kong/72 occurred in 38% of R-75 strain monovalent vaccinees, 14% of Alice/R-75 2-dose vaccinees and 11% of Alice/R-75 one dose vaccinees. An epidemic of influenza at the onset of the study made evaluation of the efficacy of the vaccine impossible.

Copyright information

© Springer-Verlag 1979

Authors and Affiliations

  • Mary J. Spencer
    • 1
  • James D. Cherry
    • 1
  • Keith R. Powell
    • 1
  • Ciro V. Sumaya
    • 1
  1. 1.The Department of Pediatrics, Division of Ambulatory Pediatrics and Infectious DiseasesUCLA School of MedicineLos AngelesUSA

Personalised recommendations